{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:55:13Z","timestamp":1794653713073,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Intramural"],"award-info":[{"award-number":["Intramural"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cas9 proteins are derived from human pathogens and are immunogenic, thereby raising potential safety concerns and limiting clinical effectiveness when using Cas9 as a gene-editing tool. Cas orthologs developed from organisms not directly associated with human infections may thus be safer. Here we compare the immunogenicity risk of SaCas9 (derived from the human pathogen,\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    ), AsCas12a (derived from the human commensal,\n                    <jats:italic>Acidaminococcus<\/jats:italic>\n                    sp.) and Cas\u03a6 (derived from a bacteria phage, Biggiephage). Ex vivo and in vitro analyses show that SaCas9, AsCas12a and Cas\u03a6 are recognized similarly by antibodies and T cells from unimmunized individuals. Using mass-spectrometry to identify MHC-I-bound peptides, we find SaCas9, AsCas12a and Cas\u03a6 peptides presented on 9 MHC-I proteins commonly found in the North American population. Our results thus indicate that AsCas12a and Cas\u03a6 do not present a less immunogenic alternative to Cas9, and underscore the need for systematic immunogenicity evaluation of all Cas proteins intended for clinical use.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-75015-7","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:02:25Z","timestamp":1782896545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pre-existing antibody and T cell responses to SaCas9, AsCas12a and Cas\u03a6 are comparable in na\u00efve individuals"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-5250","authenticated-orcid":false,"given":"Vijaya L.","family":"Simhadri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-7369","authenticated-orcid":false,"given":"Pratima","family":"Bajgain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Vijayanand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-9057","authenticated-orcid":false,"given":"Wojciech","family":"Jankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-693X","authenticated-orcid":false,"given":"Atul","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Thijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van Doninck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Pattyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Pepermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-5188","authenticated-orcid":false,"given":"Zuben E.","family":"Sauna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"75015_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","volume":"164","author":"AV Wright","year":"2016","unstructured":"Wright, A. V., Nu\u00f1ez, J. K. & Doudna, J. A. Biology and applications of CRISPR systems: harnessing nature\u2019s toolbox for genome engineering. Cell 164, 29\u201344 (2016).","journal-title":"Cell"},{"key":"75015_CR2","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41580-019-0131-5","volume":"20","author":"A Pickar-Oliver","year":"2019","unstructured":"Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR-Cas technologies and applications. Nat. Rev. Mol. Cell Biol. 20, 490\u2013507 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75015_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.699597","volume":"9","author":"SA Abdelnour","year":"2021","unstructured":"Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E. & Lu, Y. The potential of CRISPR\/Cas9 gene editing as a treatment strategy for inherited diseases. Front Cell Dev. Biol. 9, 699597 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"75015_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28137-7","volume":"13","author":"S Riesenberg","year":"2022","unstructured":"Riesenberg, S., Helmbrecht, N., Kanis, P., Maricic, T. & P\u00e4\u00e4bo, S. Improved gRNA secondary structures allow editing of target sites resistant to CRISPR-Cas9 cleavage. Nat. Commun. 13, 489 (2022).","journal-title":"Nat. Commun."},{"key":"75015_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119711","volume":"234","author":"Y Li","year":"2020","unstructured":"Li, Y., Glass, Z., Huang, M., Chen, Z. Y. & Xu, Q. Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications. Biomaterials 234, 119711 (2020).","journal-title":"Biomaterials"},{"key":"75015_CR6","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944204","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums, D. V. Editorial: first regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-Thalassemia. Med Sci. Monit. 30, e944204 (2024).","journal-title":"Med Sci. Monit."},{"key":"75015_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","volume":"5","author":"H Li","year":"2020","unstructured":"Li, H. et al. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct. Target Ther. 5, 1 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"75015_CR8","doi-asserted-by":"publisher","first-page":"1342193","DOI":"10.3389\/fgeed.2024.1342193","volume":"6","author":"A Macarr\u00f3n Palacios","year":"2024","unstructured":"Macarr\u00f3n Palacios, A., Korus, P., Wilkens, B. G. C., Heshmatpour, N. & Patnaik, S. R. Revolutionizing in vivo therapy with CRISPR\/Cas genome editing: breakthroughs, opportunities and challenges. Front Genome Ed. 6, 1342193 (2024).","journal-title":"Front Genome Ed."},{"key":"75015_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","volume":"266","author":"C Liu","year":"2017","unstructured":"Liu, C., Zhang, L., Liu, H. & Cheng, K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J. Control Release 266, 17\u201326 (2017).","journal-title":"J. Control Release"},{"key":"75015_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"75015_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"75015_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-018-0127-2","volume":"12","author":"A Biagioni","year":"2018","unstructured":"Biagioni, A. et al. Delivery systems of CRISPR\/Cas9-based cancer gene therapy. J. Biol. Eng. 12, 33 (2018).","journal-title":"J. Biol. Eng."},{"key":"75015_CR13","doi-asserted-by":"publisher","first-page":"e2413519121","DOI":"10.1073\/pnas.2413519121","volume":"122","author":"W Ngo","year":"2025","unstructured":"Ngo, W. et al. Mechanism-guided engineering of a minimal biological particle for genome editing. Proc. Natl. Acad. Sci. USA 122, e2413519121 (2025).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75015_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li, T. et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct. Target. Ther. 8, 36 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"75015_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1445-x","volume":"19","author":"Y Wang","year":"2018","unstructured":"Wang, Y. et al. Systematic evaluation of CRISPR-Cas systems reveals design principles for genome editing in human cells. Genome Biol. 19, 62 (2018).","journal-title":"Genome Biol."},{"key":"75015_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0817-8","volume":"16","author":"AE Friedland","year":"2015","unstructured":"Friedland, A. E. et al. Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol. 16, 257 (2015).","journal-title":"Genome Biol."},{"key":"75015_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"75015_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38039-x","volume":"14","author":"SB Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).","journal-title":"Nat. Commun."},{"key":"75015_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","volume":"10","author":"VL Simhadri","year":"2018","unstructured":"Simhadri, V. L. et al. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol. Ther. Methods Clin. Dev. 10, 105\u2013112 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"75015_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner, D. L. et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat. Med 25, 242\u2013248 (2019).","journal-title":"Nat. Med"},{"key":"75015_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med 25, 249\u2013254 (2019).","journal-title":"Nat. Med"},{"key":"75015_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25414-9","volume":"12","author":"VL Simhadri","year":"2021","unstructured":"Simhadri, V. L. et al. Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4(+) T cells. Nat. Commun. 12, 5090 (2021).","journal-title":"Nat. Commun."},{"key":"75015_CR23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrmicro3569","volume":"13","author":"KS Makarova","year":"2015","unstructured":"Makarova, K. S. et al. An updated evolutionary classification of CRISPR-Cas systems. Nat. Rev. Microbiol 13, 722\u2013736 (2015).","journal-title":"Nat. Rev. Microbiol"},{"key":"75015_CR24","doi-asserted-by":"publisher","first-page":"aad5147","DOI":"10.1126\/science.aad5147","volume":"353","author":"P Mohanraju","year":"2016","unstructured":"Mohanraju, P. et al. Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems. Science 353, aad5147 (2016).","journal-title":"Science"},{"key":"75015_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12934-020-01431-z","volume":"19","author":"Z Liu","year":"2020","unstructured":"Liu, Z., Dong, H., Cui, Y., Cong, L. & Zhang, D. Application of different types of CRISPR\/Cas-based systems in bacteria. Micro Cell Fact. 19, 172 (2020).","journal-title":"Micro Cell Fact."},{"key":"75015_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.molcel.2021.12.002","volume":"82","author":"G Liu","year":"2022","unstructured":"Liu, G., Lin, Q., Jin, S. & Gao, C. The CRISPR-Cas toolbox and gene editing technologies. Mol. Cell 82, 333\u2013347 (2022).","journal-title":"Mol. Cell"},{"key":"75015_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1126\/science.abb1400","volume":"369","author":"P Pausch","year":"2020","unstructured":"Pausch, P. et al. CRISPR-Cas\u03a6 from huge phages is a hypercompact genome editor. Science 369, 333\u2013337 (2020).","journal-title":"Science"},{"key":"75015_CR28","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1038\/s41591-022-01848-6","volume":"28","author":"XE Tang","year":"2022","unstructured":"Tang, X. E., Tan, S. X., Hoon, S. & Yeo, G. W. Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans. Nat. Med 28, 1372\u20131376 (2022).","journal-title":"Nat. Med"},{"key":"75015_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.it.2016.08.010","volume":"37","author":"KL Rock","year":"2016","unstructured":"Rock, K. L., Reits, E. & Neefjes, J. Present Yourself! By MHC class I and MHC class II molecules. Trends Immunol. 37, 724\u2013737 (2016).","journal-title":"Trends Immunol."},{"key":"75015_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.immunol.18.1.1","volume":"18","author":"HO McDevitt","year":"2000","unstructured":"McDevitt, H. O. Discovering the role of the major histocompatibility complex in the immune response. Annu Rev. Immunol. 18, 1\u201317 (2000).","journal-title":"Annu Rev. Immunol."},{"key":"75015_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-genom-091212-153455","volume":"14","author":"J Trowsdale","year":"2013","unstructured":"Trowsdale, J. & Knight, J. C. Major histocompatibility complex genomics and human disease. Annu Rev. Genomics Hum. Genet 14, 301\u2013323 (2013).","journal-title":"Annu Rev. Genomics Hum. Genet"},{"key":"75015_CR32","doi-asserted-by":"crossref","unstructured":"McGill, J. R., Yogurtcu, O. N., Verthelyi, D., Yang, H. & Sauna, Z. E. SampPick: selection of a cohort of subjects matching a population HLA distribution. Front. Immunol. 10, 2894 (2019).","DOI":"10.3389\/fimmu.2019.02894"},{"key":"75015_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41434-021-00301-6","volume":"30","author":"VL Simhadri","year":"2023","unstructured":"Simhadri, V. L., McGill, J. R. & Sauna, Z. E. Endotoxin contamination in commercially available Cas9 proteins potentially induces T cell mediated responses. Gene Ther. 30, 575\u2013580 (2023).","journal-title":"Gene Ther."},{"key":"75015_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55522-1","volume":"16","author":"R Raghavan","year":"2025","unstructured":"Raghavan, R. et al. Rational engineering of minimally immunogenic nucleases for gene therapy. Nat. Commun. 16, 105 (2025).","journal-title":"Nat. Commun."},{"key":"75015_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1271120","volume":"14","author":"W Jankowski","year":"2023","unstructured":"Jankowski, W. et al. The MHC associated peptide proteomics assay is a useful tool for the non-clinical assessment of immunogenicity. Front Immunol. 14, 1271120 (2023).","journal-title":"Front Immunol."},{"key":"75015_CR36","doi-asserted-by":"publisher","unstructured":"Karle, A. C. Applying MAPPs assays to assess drug immunogenicity. Front. Immunol. 11. https:\/\/doi.org\/10.3389\/fimmu.2020.00698.","DOI":"10.3389\/fimmu.2020.00698"},{"key":"75015_CR37","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1182\/bloodadvances.2018030452","volume":"3","author":"W Jankowski","year":"2019","unstructured":"Jankowski, W. et al. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products. Blood Adv. 3, 1429\u20131440 (2019).","journal-title":"Blood Adv."},{"key":"75015_CR38","doi-asserted-by":"publisher","unstructured":"Du, H. et al. Targeting peptide antigens using a multiallelic MHC I-binding system. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02505-8.","DOI":"10.1038\/s41587-024-02505-8"},{"key":"75015_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-9433-5-1","volume":"5","author":"PA Reche","year":"2006","unstructured":"Reche, P. A. et al. Elicitation from virus-naive individuals of cytotoxic T lymphocytes directed against conserved HIV-1 epitopes. Med Immunol. 5, 1 (2006).","journal-title":"Med Immunol."},{"key":"75015_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","volume":"38","author":"S Sarkizova","year":"2020","unstructured":"Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199\u2013209 (2020).","journal-title":"Nat. Biotechnol."},{"key":"75015_CR41","doi-asserted-by":"publisher","first-page":"835454","DOI":"10.3389\/fimmu.2022.835454","volume":"13","author":"S Kaabinejadian","year":"2022","unstructured":"Kaabinejadian, S. et al. Accurate MHC motif deconvolution of immunopeptidomics data reveals a significant contribution of DRB3, 4 and 5 to the total DR immunopeptidome. Front. Immunol. 13, 835454 (2022).","journal-title":"Front. Immunol."},{"key":"75015_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09693-x","volume":"10","author":"SR Ferdosi","year":"2019","unstructured":"Ferdosi, S. R. et al. Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes. Nat. Commun. 10, 1842 (2019).","journal-title":"Nat. Commun."},{"key":"75015_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05843-9","volume":"9","author":"JM Crudele","year":"2018","unstructured":"Crudele, J. M. & Chamberlain, J. S. Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat. Commun. 9, 3497 (2018).","journal-title":"Nat. Commun."},{"key":"75015_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24017-8","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines. Nat. Commun. 12, 3908 (2021).","journal-title":"Nat. Commun."},{"key":"75015_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nri3430","volume":"13","author":"N Kamada","year":"2013","unstructured":"Kamada, N., Seo, S. U., Chen, G. Y. & N\u00fa\u00f1ez, G. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321\u2013335 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"75015_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl3927","volume":"14","author":"I Vujkovic-Cvijin","year":"2022","unstructured":"Vujkovic-Cvijin, I. et al. The systemic anti-microbiota IgG repertoire can identify gut bacteria that translocate across gut barrier surfaces. Sci. Transl. Med. 14, eabl3927 (2022).","journal-title":"Sci. Transl. Med."},{"key":"75015_CR47","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2007-4","volume":"578","author":"B Al-Shayeb","year":"2020","unstructured":"Al-Shayeb, B. et al. Clades of huge phages from across Earth\u2019s ecosystems. Nature 578, 425\u2013431 (2020).","journal-title":"Nature"},{"key":"75015_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s13337-021-00673-8","volume":"32","author":"A Archana","year":"2021","unstructured":"Archana, A., Patel, P. S., Kumar, R. & Nath, G. Neutralizing antibody response against subcutaneously injected bacteriophages in rabbit model. Virusdisease 32, 38\u201345 (2021).","journal-title":"Virusdisease"},{"key":"75015_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47192-w","volume":"15","author":"JD Berkson","year":"2024","unstructured":"Berkson, J. D. et al. Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin resistant Enterococcus in a murine model. Nat. Commun. 15, 2993 (2024).","journal-title":"Nat. Commun."},{"key":"75015_CR50","doi-asserted-by":"crossref","unstructured":"Majewska, J. et al. Induction of phage-specific antibodies by two therapeutic staphylococcal bacteriophages administered per OS. Front. Immunol. 10, 2607 (2019).","DOI":"10.3389\/fimmu.2019.02607"},{"key":"75015_CR51","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1111\/jphp.12810","volume":"70","author":"AS Rosenberg","year":"2018","unstructured":"Rosenberg, A. S. & Sauna, Z. E. Immunogenicity assessment during the development of protein therapeutics. J. Pharm. Pharmacol. 70, 584\u2013594 (2018).","journal-title":"J. Pharm. Pharmacol."},{"key":"75015_CR52","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tibtech.2018.05.008","volume":"36","author":"ZE Sauna","year":"2018","unstructured":"Sauna, Z. E., Lagass\u00e9, D., Pedras-Vasconcelos, J., Golding, B. & Rosenberg, A. S. Evaluating and mitigating the immunogenicity of therapeutic proteins. Trends Biotechnol. 36, 1068\u20131084 (2018).","journal-title":"Trends Biotechnol."},{"key":"75015_CR53","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","volume":"28","author":"A Li","year":"2020","unstructured":"Li, A. et al. AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9. Mol. Ther. 28, 1432\u20131441 (2020).","journal-title":"Mol. Ther."},{"key":"75015_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26830-7","volume":"12","author":"CH Hakim","year":"2021","unstructured":"Hakim, C. H. et al. Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models. Nat. Commun. 12, 6769 (2021).","journal-title":"Nat. Commun."},{"key":"75015_CR55","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235\u20132243 (2025).","journal-title":"N. Engl. J. Med."},{"key":"75015_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-immunol-082119-124838","volume":"38","author":"B Peters","year":"2020","unstructured":"Peters, B., Nielsen, M. & Sette, A. T cell epitope predictions. Annu Rev. Immunol. 38, 123\u2013145 (2020).","journal-title":"Annu Rev. Immunol."},{"key":"75015_CR57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.immuni.2017.02.007","volume":"46","author":"JG Abelin","year":"2017","unstructured":"Abelin, J. G. et al. Mass spectrometry profiling of HLA-associated peptidomes in mono-allelic cells enables more accurate epitope prediction. Immunity 46, 315\u2013326 (2017).","journal-title":"Immunity"},{"key":"75015_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41551-023-01129-8","volume":"8","author":"SJ Bing","year":"2024","unstructured":"Bing, S. J. et al. Rational immunosilencing of a promiscuous T cell epitope in the capsid of an adeno-associated virus. Nat. Biomed. Eng. 8, 193\u2013200 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"75015_CR59","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1286","volume":"9","author":"K Lamberth","year":"2017","unstructured":"Lamberth, K. et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools. Sci. Transl. Med. 9, eaag1286 (2017).","journal-title":"Sci. Transl. Med."},{"key":"75015_CR60","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nmeth.3993","volume":"13","author":"WL Chew","year":"2016","unstructured":"Chew, W. L. et al. A multifunctional AAV\u2013CRISPR\u2013Cas9 and its host response. Nat. Methods 13, 868\u2013874 (2016).","journal-title":"Nat. Methods"},{"key":"75015_CR61","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J.-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24, 1012\u20131019 (2014).","journal-title":"Genome Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75015-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75015-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:30:19Z","timestamp":1786404619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75015-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75015"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75015-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.E.S., V.L.S., P.B., S.V., W.J., and A.R. have no competing interests. E.P. is the Co-founder and CEO of IMMUNESPEC. L.T., T.V.D., and K.B. are employees of IMMUNESPEC. S.P. is the CTO of IQVIA Laboratories.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8166"}}